Cutter & CO Brokerage Inc. increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Get Rating) by 0.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 46,251 shares of the company’s stock after buying an additional 332 shares during the quarter. Novo Nordisk A/S makes up approximately 1.4% of Cutter & CO Brokerage Inc.’s investment portfolio, making the stock its 13th largest position. Cutter & CO Brokerage Inc.’s holdings in Novo Nordisk A/S were worth $5,180,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of NVO. Mathes Company Inc. purchased a new stake in Novo Nordisk A/S in the fourth quarter worth $1,930,000. Ahrens Investment Partners LLC purchased a new stake in Novo Nordisk A/S in the fourth quarter worth $25,000. Bell Investment Advisors Inc purchased a new stake in Novo Nordisk A/S in the third quarter worth $28,000. Allegheny Financial Group LTD purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $34,000. Finally, Clearstead Advisors LLC grew its position in shares of Novo Nordisk A/S by 109.3% in the third quarter. Clearstead Advisors LLC now owns 314 shares of the company’s stock valued at $30,000 after purchasing an additional 164 shares in the last quarter.
NVO has been the subject of several recent research reports. Liberum Capital cut Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, January 25th. Danske upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, February 3rd. Berenberg Bank lifted their price target on Novo Nordisk A/S from 585.00 to 780.00 and gave the company a “hold” rating in a research report on Tuesday, April 19th. Cowen upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Monday, April 25th. Finally, Barclays lifted their price target on Novo Nordisk A/S from 750.00 to 850.00 in a research report on Thursday, April 14th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $559.33.
Novo Nordisk A/S (NYSE:NVO – Get Rating) last issued its quarterly earnings data on Friday, April 29th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.09. The firm had revenue of $6.34 billion during the quarter, compared to analyst estimates of $5.82 billion. Novo Nordisk A/S had a return on equity of 72.67% and a net margin of 33.16%. On average, analysts predict that Novo Nordisk A/S will post 3.38 earnings per share for the current year.
The firm also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 5th. Investors of record on Monday, March 28th were given a dividend of $0.741 per share. The ex-dividend date of this dividend was Friday, March 25th. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.56. This represents a yield of 1.1%. Novo Nordisk A/S’s payout ratio is currently 44.05%.
About Novo Nordisk A/S (Get Rating)
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
- Get a free copy of the StockNews.com research report on Novo Nordisk A/S (NVO)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.